Lexeo Therapeutics, Inc. (LXEO:NASDAQ) closed at $2.74 on October 13, 2026, down 9.87% on the day. It is trading at its 52-week low of $2.74. Over the past year, it lost 67.8%. Lexeo Therapeutics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -15.17% | -34.92% | -39.91% | -60.35% | -67.76% |
In 252 trading sessions since October 13, 2025, LXEO closed higher on 117 days (46%). Its best day was May 20, 2026 (+14.29%) and its worst was January 12, 2026 (-22.96%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 1 time.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Find more stocks like LXEO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.